Bluebird Bio Inc. (NASDAQ:BLUE) – Investment analysts at Roth Capital issued their Q3 2016 earnings estimates for shares of Bluebird Bio in a report released on Thursday. Roth Capital analyst M. Breidenbach anticipates that the firm will earn ($1.71) per share for the quarter. Roth Capital has a “Buy” rating and a $87.00 price target on the stock. Roth Capital also issued estimates for Bluebird Bio’s Q4 2016 earnings at ($1.72) EPS, FY2016 earnings at ($6.55) EPS, Q1 2017 earnings at ($1.87) EPS, Q2 2017 earnings at ($1.89) EPS, Q3 2017 earnings at ($1.93) EPS, Q4 2017 earnings at ($1.89) EPS, FY2017 earnings at ($7.57) EPS and FY2019 earnings at ($1.49) EPS.
A number of other brokerages have also issued reports on BLUE. Wedbush reaffirmed an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a research note on Wednesday, August 3rd. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $135.00 price target on shares of Bluebird Bio in a research note on Thursday, September 8th. Leerink Swann reaffirmed a “buy” rating on shares of Bluebird Bio in a research note on Monday, June 13th. Piper Jaffray Cos. set a $95.00 price target on Bluebird Bio and gave the company a “buy” rating in a research note on Thursday, September 8th. Finally, Vetr lowered Bluebird Bio from a “strong-buy” rating to a “sell” rating and set a $44.44 price target for the company. in a research note on Wednesday, June 8th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $89.17.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 72.97 on Monday. The stock’s market cap is $2.71 billion. Bluebird Bio has a 52-week low of $35.37 and a 52-week high of $106.95. The firm’s 50-day moving average price is $58.81 and its 200-day moving average price is $48.79.
Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The business earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. Bluebird Bio’s revenue for the quarter was down 68.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.57) EPS.
Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP purchased a new stake in shares of Bluebird Bio during the first quarter valued at about $51,095,000. BlackRock Inc. raised its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock valued at $3,363,000 after buying an additional 1,682 shares in the last quarter. Iguana Healthcare Management LLC purchased a new stake in shares of Bluebird Bio during the first quarter valued at about $1,030,000. Finally, Swiss National Bank raised its stake in shares of Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares in the last quarter.
In related news, insider David Davidson sold 1,000 shares of the stock in a transaction on Friday, July 15th. The stock was sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the sale, the insider now directly owns 10,600 shares in the company, valued at $477,848. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Eric Sullivan sold 2,912 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total value of $160,189.12. Following the sale, the insider now owns 4,456 shares of the company’s stock, valued at $245,124.56. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.